Educational Webinars

BENEFIT-ALS: Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv


Jeremy Shefner, MD (SUNY Upstate Medical University), Jinsy Andrews, MD (Cytokinetics, Inc.), and Andrew Wolff, MD (Cytokinetics, Inc.) discussed rationale and background of the phase IIB trial of tirasmetiv in ALS.